Vimian Group AB
Research Vimian Group AB (VIMIAN) on Bullrun: valuation model: 12.5% undervalued, market cap SEK 15.69B, P/E 38.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVIMIAN
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencySEK
- Valuation signal12.5% undervalued
- Market capSEK 15.69B
- P/E38.7
- Financial periodQ4 2025
- RevenueSEK 109.00M
- Net incomeSEK 12.10M
- Free cash flowSEK 49.90M
- Gross margin67.6%
Valuation Snapshot
Bullrun's latest valuation model marks Vimian Group AB as 12.5% undervalued; latest market cap is SEK 15.69B; P/E is 38.7.
About Vimian Group AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name;
Frequently asked questions
Is Vimian Group AB overvalued or undervalued?
Bullrun's valuation model currently marks Vimian Group AB as 12.5% undervalued.
What is Vimian Group AB's market cap?
Vimian Group AB's market capitalization is SEK 15.69B.
What is Vimian Group AB's P/E ratio?
Vimian Group AB's price-to-earnings (P/E) ratio is 38.7.
What does Vimian Group AB do?
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services.